The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).
 
Motoko Tachihara
Honoraria - AstraZeneca Japan
 
Naoko Chayahara
No Relationships to Disclose
 
Yoshimi Fujishima
No Relationships to Disclose
 
Atsushi Fukunaga
No Relationships to Disclose
 
Ken Washio
No Relationships to Disclose
 
Masatsugu Yamamoto
No Relationships to Disclose
 
Kyosuke Nakata
No Relationships to Disclose
 
Kazuyuki Kobayashi
No Relationships to Disclose
 
Kei Takenaka
No Relationships to Disclose
 
Masanori Toyoda
Employment - Shionogi (I)
Speakers' Bureau - Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Naomi Kiyota
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Kazutoshi Tobimatsu
No Relationships to Disclose
 
Hisayo Doi
No Relationships to Disclose
 
Naomi Mizuta
No Relationships to Disclose
 
Naho Marugami
No Relationships to Disclose
 
Atsushi Kawaguchi
No Relationships to Disclose
 
Chikako Nishigori
No Relationships to Disclose
 
Yoshihiro Nishimura
No Relationships to Disclose
 
Toru Mukohara
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Novartis; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
 
Hironobu Minami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanofi; Shire; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Merck Serono; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)